Overview

Mood Disorders in Head and Neck Cancer Patients

Status:
Not yet recruiting

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to initiate a pharmacotherapy protocol for at-risk patients with newly diagnosed head and neck cancer in order to decrease the incidence of anxiety, depression, and uncontrolled pain during cancer treatment.

Phase:

Phase 4

Details

Lead Sponsor:

University of Alabama at Birmingham

Treatments:

Venlafaxine Hydrochloride